|
1) Nyberg P, Xie L, Kalluri R. Endogenous inhibitors of angiogenesis. Cancer Res. 2005; 65: 3967-79
|
|
|
|
2) Ambati BK, Nozaki M, Singh N, et al. Corneal avascularity is due to soluble VEGF receptor-1. Nature. 2006; 443: 993-7
|
|
|
|
|
|
3) Eremina V, Jefferson JA, Kowalewska J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med. 2008; 358: 1129-36
|
|
|
|
|
|
4) Vuorela-Vepsalainen P, Alfthan H, Orpana A, et al. Vascular endothelial growth factor is bound in amniotic fluid and maternal serum. Hum Reprod. 1999; 14: 1346-51
|
|
|
|
|
|
5) Vuorela P, Helske S, Hornig C, et al. Amniotic fluid–soluble vascular endothelial growth factor receptor-1 in preeclampsia. Obstet Gynecol. 2000; 95: 353-7
|
|
|
|
|
|
6) Zhou Y, McMaster M, Woo K, et al. Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. Am J Pathol. 2002; 160: 1405-23
|
|
|
|
|
|
7) Sugimoto H, Hamano Y, Charytan D, et al. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem. 2003; 278: 12605-8
|
|
|
|
|
|
8) Maynard SE, Min JY, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003; 111: 649-58
|
|
|
|
|
|
9) Mahasreshti PJ, Kataram M, Wang MH, et al. Intravenous delivery of adenovirus-mediated soluble FLT-1 results in liver toxicity. Clin Cancer Res. 2003; 9: 2701-10
|
|
|
|
|
|
10) Kumasawa K, Ikawa M, Kidoya H, et al. Pravastatin induces placental growth factor (PGF) and ameliorates preeclampsia in a mouse model. Proc Natl Acad Sci U S A. 2011; 108: 1451-5
|
|
|
|
|
|
11) Sela S, Itin A, Natanson-Yaron S, et al. A novel human-specific soluble vascular endothelial growth factor receptor 1: cell-type-specific splicing and implications to vascular endothelial growth factor homeostasis and preeclampsia. Circ Res. 2008; 102: 1566-74
|
|
|
|
|
|
12) Zhao S, Gu Y, Fan R, et al. Proteases and sFlt-1 release in the human placenta. Placenta. 2010; 31: 512-8
|
|
|
|
|
|
13) Kanasaki K, Kalluri R. The biology of preeclampsia. Kidney Int. 2009; 76: 831-7
|
|
|
|
|
|
14) Barnea ER, MacLusky NJ, DeCherney AH, et al. Catechol-o-methyl transferase activity in the human term placenta. Am J Perinatol. 1988; 5: 121-7
|
|
|
|
|
|
15) Kanasaki K, Palmsten K, Sugimoto H, et al. Deficiency in catechol-O-methyltransferase and 2-methoxyoestradiol is associated with pre-eclampsia. Nature. 2008; 453: 1117-21
|
|
|
|
|
|
16) Kliman H, Nestler J, Sermasi E, et al. Purification, characterization, and in vitro differentiation of cytotrophoblasts from human term placentae. Endocrinology. 1986; 118: 1567-82
|
|
|
|
|
|
17) Lee SB, Wong AP, Kanasaki K, et al. Preeclampsia: 2-methoxyestradiol induces cytotrophoblast invasion and vascular development specifically under hypoxic conditions. Am J Pathol. 2010; 176: 710-20
|
|
|
|
|
|
18) Sata F, Yamada H, Suzuki K, et al. Functional maternal catechol-O-methyltransferase polymorphism and fetal growth restriction. Pharmacogenet Genomics. 2006; 16: 775-81
|
|
|
|
|
|
19) Tunbridge EM, Harrison PJ, Weinberger DR. Catechol-o-methyltransferase, cognition, and psychosis: Val158Met and beyond. Biol Psychiatry. 2006; 60: 141-51. Epub 2006 Feb 2014
|
|
|
|
|
|
20) Nackley AG, Shabalina SA, Tchivileva IE, et al. Human catechol-O-methyltransferase haplotypes modulate protein expression by altering mRNA secondary structure. Science. 2006; 314: 1930-3
|
|
|
|
|
|
21) Lim JH, Kim SY, Kim do J, et al. Genetic polymorphism of catechol-O-methyltransferase and cytochrome P450c17alpha in preeclampsia. Pharmacogenet Genomics. 2010; 20: 605-10
|
|
|
|
|
|
22) Roten LT, Fenstad MH, Forsmo S, et al. A low COMT activity haplotype is associated with recurrent preeclampsia in a Norwegian population cohort (HUNT2). Mol Hum Reprod. 2011; 17: 439-46
|
|
|
|
|
|
23) Hill LD, York TP, Kusanovic JP, et al. Epistasis between COMT and MTHFR in maternal-fetal dyads increases risk for preeclampsia. PLoS One. 2011; 6: e16681
|
|
|
|
|
|
24) Zhou, CC, Zhang Y, Irani RA, et al. Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice. Nat Med. 2008; 14: 855-62
|
|
|
|
|
|
25) LaMarca BD, Alexander BT, Gilbert JS, et al. Pathophysiology of hypertension in response to placental ischemia during pregnancy: a central role for endothelin？ Gend Med. 2008; 5 Suppl A: S133-8
|
|
|
|
|
|
26) Zhang SL, Du YH, Wang J, et al. Endothelial dysfunction induced by antibodies against angiotensin AT1 receptor in immunized rats. Acta Pharmacol Sin. 2010; 31: 1381-8
|
|
|
|
|
|
27) Wenzel K, Rajakumar A, Haase H, et al. Angiotensin II type 1 receptor antibodies and increased angiotensin II sensitivity in pregnant rats. Hypertension. 2011; 58: 77-84
|
|
|
|
|
|
28) Gant NF, Daley GL, Chand S, et al. A study of angiotensin II pressor response throughout primigravid pregnancy. J Clin Invest. 1973; 52: 2682-9
|
|
|
|
|